The Life Sciences Catalyst

This is the 16th edition of Measuring the return from pharmaceutical innovation. This year the analysis shows an industry at an inflection point. While headline pharmaceutical research and development (R&D) returns have improved for the third consecutive year, reaching a 7.0 per cent internal rate of return (IRR) in 2025, this recovery is largely driven by a few mega-blockbuster programmes, notably glucagon-like peptide receptor agonists (GLP-1s) and GLP-1 combinations with gastric inhibitory polypeptide-based drugs (GIPs) in obesity, masking broader R&D pressures.

View our latest insight here.

Our latest insight on Biotech European expansion covers the choices to consider for:

• A successful launch strategy: Including market access sequencing, pricing strategy, and commercial readiness.
• G&A functions to support a lean launch: Understanding the capabilities needed and forming an outsourcing strategy.
• Risk mitigation: Structuring a biotech from a tax perspective and building a global organisation.

View our latest insight here

This is the fourth of a series of life sciences and healthcare predictions reports, compromising ten predictions exploring how the world could look in 2030, what it might feel like for different stakeholders in the health ecosystem, the evidence today that informs our views of tomorrow and how AI technologies, specifically GenAI, might help bring the future closer.

View all predictions here

The go-to-market strategies deployed by emerging biotechs to launch their first products into Europe have changed in the last two years. Instead of building their own infrastructure, emerging biotechs are primarily commercialising their products through out-licencing agreements.

View our latest insight here

In recent years, companies operating in the Life Sciences and Healthcare (LSHC) sector are more and more participating in open innovation to overcome various R&D and commercial challenges. The concept of open innovation involves sourcing new technologies, skills, and knowledge from third parties versus adopting more traditional or closed in-house development models. Overall, biopharma assets sourced via open innovation approaches are currently demonstrating a higher probability of later-phase clinical success compared to those from closed model product development. For large pharma companies this is leading to more cost and time effective product development and is shortening the time to market as well as providing wider access to talent, new technologies, broader geographies, and different therapeutic areas. For smaller pharma and biotech companies, open innovation is leading to increased partnerships and out-licensing opportunities, but this is not without challenges. To help smaller LSHC companies better navigate open innovation, Deloitte’s IP Advisory team has identified key areas to address to ensure more successful outcomes including when to seek a partner, identifying the right partner, preparing materials, and deal negotiations skills.

View our latest report here